<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157548">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048658</url>
  </required_header>
  <id_info>
    <org_study_id>IRB - 5146</org_study_id>
    <nct_id>NCT01048658</nct_id>
  </id_info>
  <brief_title>Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures</brief_title>
  <official_title>Sevoflurane as an Anesthetic During Dilation and Evacuation Procedures: Does it Increase Blood Loss and Interventions for Blood Loss and Why Do Anesthesiologists Choose to Use It?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sevoflurane is an FDA-approved anesthetic drug commonly used for anesthesia during second
      trimester abortion procedures. It has a few advantages, including ease of use by the
      anesthesia provider. However, the literature suggests that when used in doses higher than
      those used at OHSU and Lovejoy, it is associated with an increase in the risk of bleeding.
      The investigators study aims to test whether the lower dose used at OHSU and Lovejoy during
      second trimester abortion procedures causes any difference in blood loss, when compared to
      similar abortion procedures for which this drug is not used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study seeks to examine the bleeding complications associated with use of sevoflurane in
      general anesthesia regimens for second trimester abortion procedures and assess anesthesia
      providers' use and beliefs regarding possible risks associated with newer inhalational
      agents such as sevoflurane in this setting. Participants' anesthesia will either be
      intravenous (IV) propofol, IV midazolam, IV fentanyl and nitrous oxide or this same regimen
      combined with sevoflurane during maintenance of anesthesia. Procedural outcomes,
      specifically those related to bleeding complications, including need to intervene for excess
      blood loss, will be recorded and analyzed to establish if such a relationship between use of
      sevoflurane and excess blood loss exists.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for intervention to treat blood loss (a composite of use of uterotonics, re-aspiration, and bimanual massage)</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean blood loss</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time: t-test (time of speculum placement to time speculum removed)</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfer to another facility, perforation, need for surgery (laparotomy) or hospitalization</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects (nausea, dizziness)</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and Provider feedback</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Blood Loss</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Sevoflurane</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject receives standard of care drug regimens for anesthesia with this procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>Ultane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Sevoflurane</intervention_name>
    <description>Subject only standard of care drug regimens for anesthesia with this procedure.</description>
    <arm_group_label>No Sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntarily requesting pregnancy termination

          -  Estimated gestational age of 18 weeks - 23 weeks, 6 days gestational age as
             calculated by fetal biparietal diameter on clinic ultrasound.

          -  Be able and willing to sign an informed consent and agree to terms of the study

        Exclusion Criteria:

          -  Known severe maternal respiratory disease or upper respiratory infection or sinus
             blockage

          -  Anticoagulation use: within 24 hours if Lovenox, or within 12 hours if heparin, (Must
             have a documented normal INR prior to procedure if on anticoagulation)

          -  Multiple pregnancy

          -  Fetal demise, if more than 2 weeks difference exists between known gestational age
             (by previous US dating) and gestational size on current ultrasound.

          -  Known allergy/sensitivity to sevoflurane or any other inhaled anesthetic agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosanne Botha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lovejoy Surgicenter</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Socio-Economic Factbook, S.A. Department, Editor. 1993, American College of Surgeons: Chicago, IL.</citation>
  </reference>
  <reference>
    <citation>Paul, M., A Clinician's Guide to Medical and Surgical Abortion. 1999, New York, New York: Church Livingstone.</citation>
  </reference>
  <reference>
    <citation>Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol. 1983 Aug;62(2):185-90.</citation>
    <PMID>6866362</PMID>
  </reference>
  <reference>
    <citation>Method, weeks of gestation key in abortion complications. Contracept Technol Update. 1980 Oct;1(7):96-7.</citation>
    <PMID>12336808</PMID>
  </reference>
  <reference>
    <citation>MacKay HT, Schulz KF, Grimes DA. Safety of local versus general anesthesia for second-trimester dilatation and evacuation abortion. Obstet Gynecol. 1985 Nov;66(5):661-5.</citation>
    <PMID>4058825</PMID>
  </reference>
  <reference>
    <citation>O'Connell K, Jones HE, Lichtenberg ES, Paul M. Second-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception. 2008 Dec;78(6):492-9. doi: 10.1016/j.contraception.2008.07.011.</citation>
    <PMID>19014796</PMID>
  </reference>
  <reference>
    <citation>Abboud TK, D'Onofrio L, Reyes A, Mosaad P, Zhu J, Mantilla M, Gangolly J, Crowell D, Cheung M, Afrasiabi A, et al. Isoflurane or halothane for cesarean section: comparative maternal and neonatal effects. Acta Anaesthesiol Scand. 1989 Oct;33(7):578-81.</citation>
    <PMID>2816239</PMID>
  </reference>
  <reference>
    <citation>West SL, Moore CA, Gillard M, Browne PD. Anaesthesia for suction termination of pregnancy. Anaesthesia. 1985 Jul;40(7):669-72.</citation>
    <PMID>4025771</PMID>
  </reference>
  <reference>
    <citation>Collins, K.M., et al., Outpatient termination of pregnancy: halothane or alfentanil-supplemented anaesthesia. Br J Anaesth, 1985. 57(12): p. 1226-31. 10. Galbert, M.W. and A.E. Gardner, Use of halothane in a balanced technic for cesarean section. Anesth Analg, 1972. 51(5): p. 701-4.</citation>
  </reference>
  <reference>
    <citation>Forrest WH Jr. Effects of anesthesia in therapeutic abortion. Anesthesiology. 1970 Jul;33(1):121-2.</citation>
    <PMID>4393415</PMID>
  </reference>
  <reference>
    <citation>Cullen BF, Margolis AJ, Eger EI 2nd. The effects of anesthesia and pulmonary ventilation on blood loss during elective therapeutic abortion. Anesthesiology. 1970 Feb;32(2):108-13.</citation>
    <PMID>4391841</PMID>
  </reference>
  <reference>
    <citation>Patel SS, Goa KL. Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia. Drugs. 1996 Apr;51(4):658-700. Review. Erratum in: Drugs 1996 Aug;52(2):253.</citation>
    <PMID>8706599</PMID>
  </reference>
  <reference>
    <citation>Yamakage M, Tsujiguchi N, Chen X, Kamada Y, Namiki A. Sevoflurane inhibits contraction of uterine smooth muscle from pregnant rats similarly to halothane and isoflurane. Can J Anaesth. 2002 Jan;49(1):62-6.</citation>
    <PMID>11782330</PMID>
  </reference>
  <reference>
    <citation>Turner RJ, Lambrost M, Holmes C, Katz SG, Downs CS, Collins DW, Gatt SP. The effects of sevoflurane on isolated gravid human myometrium. Anaesth Intensive Care. 2002 Oct;30(5):591-6.</citation>
    <PMID>12413258</PMID>
  </reference>
  <reference>
    <citation>Nathan N, Peyclit A, Lahrimi A, Feiss P. Comparison of sevoflurane and propofol for ambulatory anaesthesia in gynaecological surgery. Can J Anaesth. 1998 Dec;45(12):1148-50.</citation>
    <PMID>10051930</PMID>
  </reference>
  <reference>
    <citation>Nelskylä K, Korttila K, Yli-Hankala A. Comparison of sevoflurane-nitrous oxide and propofol-alfentanil-nitrous oxide anaesthesia for minor gynaecological surgery. Br J Anaesth. 1999 Oct;83(4):576-9.</citation>
    <PMID>10673872</PMID>
  </reference>
  <reference>
    <citation>Karaman S, Akercan F, Aldemir O, Terek MC, Yalaz M, Firat V. The maternal and neonatal effects of the volatile anaesthetic agents desflurane and sevoflurane in caesarean section: a prospective, randomized clinical study. J Int Med Res. 2006 Mar-Apr;34(2):183-92.</citation>
    <PMID>16749414</PMID>
  </reference>
  <reference>
    <citation>Gambling DR, Sharma SK, White PF, Van Beveren T, Bala AS, Gouldson R. Use of sevoflurane during elective cesarean birth: a comparison with isoflurane and spinal anesthesia. Anesth Analg. 1995 Jul;81(1):90-5.</citation>
    <PMID>7598289</PMID>
  </reference>
  <reference>
    <citation>Yeo ST, Holdcroft A, Yentis SM, Stewart A, Bassett P. Analgesia with sevoflurane during labour: ii. Sevoflurane compared with Entonox for labour analgesia. Br J Anaesth. 2007 Jan;98(1):110-5.</citation>
    <PMID>17158129</PMID>
  </reference>
  <reference>
    <citation>Jackson RA, Teplin VL, Drey EA, Thomas LJ, Darney PD. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol. 2001 Mar;97(3):471-6.</citation>
    <PMID>11239659</PMID>
  </reference>
  <reference>
    <citation>Turok DK, Gurtcheff SE, Esplin MS, Shah M, Simonsen SE, Trauscht-Van Horn J, Silver RM. Second trimester termination of pregnancy: a review by site and procedure type. Contraception. 2008 Mar;77(3):155-61. doi: 10.1016/j.contraception.2007.11.004.</citation>
    <PMID>18279684</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 4, 2013</lastchanged_date>
  <firstreceived_date>January 12, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Rosanne Botha</investigator_full_name>
    <investigator_title>Master of Public Health Student, MD</investigator_title>
  </responsible_party>
  <keyword>Sevoflurane</keyword>
  <keyword>anesthesia</keyword>
  <keyword>abortion</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
